NASDAQ: ENTA - Enanta Pharmaceuticals, Inc.

Yield per half year: -21.14%
Sector: Healthcare

Share chart Enanta Pharmaceuticals, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About

Enanta Pharmaceuticals, Inc., биотехнологическая компания, открывает и разрабатывает низкомолекулярные препараты для лечения вирусных инфекций и заболеваний печени. Его цели исследований и разработок включают респираторно-синцитиальный вирус, SARS-CoV-2, метапневмовирус человека и вирус гепатита B. Компания имеет совместную разработку и лицензионное соглашение с Abbott Laboratories для выявления, разработки и коммерциализации соединений ингибиторов протеазы NS3 и NS3/4A HCV, включая паритапревир и глекапревир для лечения хронического вируса гепатита С. Enanta Pharmaceuticals, Inc.

More details
была основана в 1995 году и имеет штаб-квартиру в Уотертауне, штат Массачусетс.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

EBITDA 0.04
EV/EBITDA 30.33
IPO date 2013-03-21
ISIN US29251M1062
Industry Biotechnology
P/BV 2.73
P/E 27.25
P/S 6.16
Sector Health Care
Валюта usd
Валюта отчета usd
Выручка 0.2052
Див.доход ао 0
Сайт https://www.enanta.com
Цена ао 10.94
Число акций ао 0.02097 млрд
Change price per day: +0% (11.04)
Change price per week: -4.42% (11.55)
Change price per month: -11.18% (12.43)
Change price per 3 month: -31.64% (16.15)
Change price per half year: -21.14% (14)
Change price per year: +14.05% (9.68)
Change price per 3 year: -84.57% (71.53)
Change price per 5 year: -84.38% (70.7)
Change price per year to date: +30.81% (8.44)
All parameters

Underestimation

Title Value Grade
P/S 2.94 6
P/BV 1.07 9
P/E 436.7 1
EV/EBITDA -1.41 0
Total: 5.75

Efficiency

Title Value Grade
ROA, % -28.95 0
ROE, % -61.74 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0.1371

Debt

Title Value Grade
Debt/EBITDA -0.2147 10
Total: 9.8

Growth impulse

Title Value Grade
Yield Revenue, % -61.4 0
Yield Ebitda, % -352.95 0
Yield EPS, % -388.49 0
Total: 0
More

Transaction date Date of disclosure Insider Type Price Volume Quantity Share before, % Share after, % Document
13.12.2023 15.12.2023 Vance Terry
Director		 Sale 9.12 139 490 15295 0 -0.08 link
05.12.2023 06.12.2023 Luly Jay R.
President and CEO		 Sale 9.63 69 625 7230 0 -0.04 link
05.12.2023 06.12.2023 MELLETT PAUL J
Sr. VP, Finance & Admin. & CFO		 Sale 9.63 23 228 2412 0 -0.01 link
05.12.2023 06.12.2023 Or Yat Sun
Sr. VP, R&D & CSO		 Sale 9.63 23 228 2412 0 -0.01 link
05.12.2023 06.12.2023 Rottinghaus Scott T.
Sr. VP & CMO		 Sale 9.63 5 142 534 0 0 link
05.12.2023 06.12.2023 Gardiner Nathaniel S.
Sr. VP & General Counsel		 Sale 9.63 23 228 2412 0 -0.01 link
05.12.2023 06.12.2023 Kieffer Tara Lynn
Sr. VP, New Prod. Strat. & Dev		 Sale 9.63 20 464 2125 0 -0.01 link
05.12.2023 06.12.2023 Luu Brendan
Sr. VP, Business Dev.		 Sale 9.63 20 464 2125 0 -0.01 link
18.04.2023 19.04.2023 Gardiner Nathaniel S.
Sr. VP & General Counsel		 Purchase 30 200 010 6667 0 0.03 link
09.01.2023 10.01.2023 MELLETT PAUL J
Treasurer and CFO		 Purchase 14.18 39 874 2812 0 0.01 link

Institutions Volume Share, %
Armistice Capital, LLC 2064000 9.76
Farallon Capital Management Llc 2025000 9.57
Blackrock Inc. 1934711 9.14
Vanguard Group Inc 1793786 8.48
Morgan Stanley 1173058 5.54
Northern Trust Corporation 935493 4.42
Acadian Asset Management. LLC 842944 3.98
Millennium Management LLC 765141 3.62
Krensavage Asset Management, LLC 742824 3.51
Shaw D.E. & Co., Inc. 638168 3.02

ETF Share, % Profitability for 1 year, % Dividends, %
Avantis U.S Small Cap Equity ETF 0.02575 27.774101036841 1.68271
Avantis Responsible U.S. Equity ETF 0.00101 26.778312788906 1.45257
Avantis U.S. Equity ETF 0.0003 30.338089728757 1.59151
Dimensional U.S. Core Equity 2 ETF 0.00038 30.755198832543 1.47098
Dimensional U.S. Targeted Value ETF 0.00117 26.007247921552 1.93487
Dimensional US Core Equity Market ETF 0.00018 30.983243755928 1.40618
Dimensional U.S. Equity ETF 0.00025 31.530984204131 1.3557
ProShares Hedge Replication ETF 0.00141 5.9237999659878 1.47892
iShares Micro-Cap ETF 0.05706 29.340359461748 1.54048
iShares Russell 3000 ETF 0.00037 30.952834139099 1.43482
Invesco FTSE RAFI US 1500 Small-Mid ETF 0.01494 30.844623810897 1.75869
Schwab U.S. Small-Cap ETF 0.00641 29.67032967033 1.51433
Schwab U.S. Broad Market ETF 0.00042 31.504006586479 1.43354
ProShares UltraPro Russell2000 0.00489 89.821266282945 1.47873
Vanguard Russell 3000 ETF 0 31.87314172448 1.43817
Vanguard Russell 2000 ETF 0.01 30.781541744465 1.48801



Head Job title Payment Year of birth
Mr. Paul J. Mellett Jr. Chief Financial & Administrative Officer 666.84k 1955 (69 years)
Dr. Yat Sun Or Ph.D. Senior VP of Research & Development and Chief Scientific Officer 729.31k 1952 (72 years)
Ms. Tara Lynn Kieffer Ph.D. Chief Product Strategy Officer 496.85k 1978 (46 years)
Mr. Brendan Luu Chief Business Officer 622.86k 1975 (49 years)
Ms. Jennifer Viera Senior Director of Investor Relations & Corporate Communications N/A
Mr. Nathaniel S. Gardiner J.D. Consultant 672.67k 1954 (70 years)
Dr. Jay R. Luly Ph.D. President, CEO & Director 1.25M 1956 (68 years)
Dr. Scott T. Rottinghaus M.D. Senior VP & Chief Medical Officer 616.73k 1974 (50 years)
Mr. Matthew P. Kowalsky J.D. Chief Legal Officer 1973 (51 year)

Address: United States, Watertown. MA, 500 Arsenal Street - open in Google maps, open in Yandex maps
Website: https://www.enanta.com